ATYR vs AVBP

aTyr Pharma, Inc. vs ArriVent BioPharma, Inc. — Valuation Comparison 2026

ATYR

Biotechnology
aTyr Pharma, Inc.
Quality
4.9
out of 10
Value Trap
52
WARN
Price
$0.49
Last close
Models
9/13
Active
VS

AVBP

Biotechnology
ArriVent BioPharma, Inc.
Quality
3.6
out of 10
Value Trap
12
SAFE
Price
$26.97
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ATYR Fair ValueATYR Upside AVBP Fair ValueAVBP Upside
Bayesian DCF Intrinsic $0.14 -71.6% $7.90 -70.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.72 +47.8% $0.59 -98.0%
Dynamic NAV Asset-Based $1.29 +164.7% $6.38 -76.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATYR vs AVBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATYR vs AVBP — Which Stock Is More Undervalued?

ATYR scores higher with a 4.9/10 quality rating vs AVBP's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing aTyr Pharma, Inc. (ATYR) and ArriVent BioPharma, Inc. (AVBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATYR currently trades at $0.49 with a QOC of 4.9/10, while AVBP trades at $26.97 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).